Navidea Biopharmaceuticals Probability of Future Pink Sheet Price Finishing Under 0.1
| NAVBDelisted Stock | USD 0.1 0.01 9.45% |
Navidea |
Navidea Biopharmaceutica Target Price Odds to finish below 0.1
The tendency of Navidea Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 0.10 after 90 days |
| 0.1 | 90 days | 0.10 | about 29.28 |
Based on a normal probability distribution, the odds of Navidea Biopharmaceutica to stay under $ 0.10 after 90 days from now is about 29.28 (This Navidea Biopharmaceuticals probability density function shows the probability of Navidea Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Navidea Biopharmaceutica price to stay between its current price of $ 0.1 and $ 0.10 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days Navidea Biopharmaceuticals has a beta of -0.36. This indicates as returns on the benchmark increase, returns on holding Navidea Biopharmaceutica are expected to decrease at a much lower rate. During a bear market, however, Navidea Biopharmaceuticals is likely to outperform the market. Additionally Navidea Biopharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Navidea Biopharmaceutica Price Density |
| Price |
Predictive Modules for Navidea Biopharmaceutica
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Navidea Biopharmaceutica. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Navidea Biopharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Navidea Biopharmaceutica Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Navidea Biopharmaceutica is not an exception. The market had few large corrections towards the Navidea Biopharmaceutica's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Navidea Biopharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Navidea Biopharmaceutica within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.06 | |
β | Beta against Dow Jones | -0.36 | |
σ | Overall volatility | 0.06 | |
Ir | Information ratio | -0.15 |
Navidea Biopharmaceutica Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Navidea Biopharmaceutica for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Navidea Biopharmaceutica can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Navidea Biopharmaceutica is not yet fully synchronised with the market data | |
| Navidea Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Navidea Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Navidea Biopharmaceuticals currently holds 2.43 M in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Navidea Biopharmaceutica has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Navidea Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Navidea Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Navidea Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Navidea to invest in growth at high rates of return. When we think about Navidea Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 65.65 K. Net Loss for the year was (15.18 M) with loss before overhead, payroll, taxes, and interest of (119.3 K). | |
| Navidea Biopharmaceuticals currently holds about 328.01 K in cash with (8.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 35.0% of Navidea Biopharmaceutica outstanding shares are owned by corporate insiders |
Navidea Biopharmaceutica Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Navidea Pink Sheet often depends not only on the future outlook of the current and potential Navidea Biopharmaceutica's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Navidea Biopharmaceutica's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 29.3 M | |
| Cash And Short Term Investments | 2 M |
Navidea Biopharmaceutica Technical Analysis
Navidea Biopharmaceutica's future price can be derived by breaking down and analyzing its technical indicators over time. Navidea Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Navidea Biopharmaceuticals. In general, you should focus on analyzing Navidea Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Navidea Biopharmaceutica Predictive Forecast Models
Navidea Biopharmaceutica's time-series forecasting models is one of many Navidea Biopharmaceutica's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Navidea Biopharmaceutica's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Navidea Biopharmaceutica
Checking the ongoing alerts about Navidea Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Navidea Biopharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Navidea Biopharmaceutica is not yet fully synchronised with the market data | |
| Navidea Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Navidea Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Navidea Biopharmaceuticals currently holds 2.43 M in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Navidea Biopharmaceutica has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Navidea Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Navidea Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Navidea Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Navidea to invest in growth at high rates of return. When we think about Navidea Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 65.65 K. Net Loss for the year was (15.18 M) with loss before overhead, payroll, taxes, and interest of (119.3 K). | |
| Navidea Biopharmaceuticals currently holds about 328.01 K in cash with (8.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 35.0% of Navidea Biopharmaceutica outstanding shares are owned by corporate insiders |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Navidea Pink Sheet
If you are still planning to invest in Navidea Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Navidea Biopharmaceutica's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |